• 1
    Vidjaya Letchoumy P, Chandra Mohan KV, Stegeman JJ, Gelboin HV, Hara Y, Nagini S. Pretreatment with black tea polyphenols modulates xenobiotic-metabolizing enzymes in an experimental oral carcinogenesis model. Oncol Res 2008; 17: 7585.
  • 2
    Steck SE, Gaudet MM, Britton JA et al. Interactions among GSTM1, GSTT1 and GSTP1 polymorphisms, cruciferous vegetable intake and breast cancer risk. Carcinogenesis 2007; 28: 19549.
  • 3
    Gemignani F, Landi S, Szeszenia-Dabrowska N et al. Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 2007; 28: 128793.
  • 4
    Qu ZQ, Li XD, Liu HL, He P, Zhang X, Wu MC. Impaired clearance of phenacetin in hepatic cirrhosis and fibrosis. Int J Clin Pharmacol Ther 2007; 45: 5562.
  • 5
    Kim DH, Kim KH, Isin EM et al. Heterologous expression and characterization of wild-type human cytochrome P450 1A2 without conventional N-terminal modification in Escherichia coli. Protein Expr Purif 2008; 57: 188200.
  • 6
    Tenmizu D, Noguchi K, Kamimura H. Elucidation of the effects of the CYP1A2 deficiency polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1h)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs. Drug Metab Dispos 2006; 34: 18116.
  • 7
    Saito Y, Hanioka N, Maekawa K et al. Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab Dispos 2005; 33: 190510.
  • 8
    Cui ZF, He P, Luo M, Xia SQ, Wu MC. Phenacetin O-deethylation in extrahepatic tissues of rats. Eur J Drug Metabo Pharmacoki 2002; 27: 10711.
  • 9
    Nash RM, Stein L, Penno MB, Passananti GT, Vesell ES. Sources of interindividual variations in acetaminophen and antipyrine metabolism. Clin Pharmacol Ther 1984; 36: 41730.
  • 10
    Suzuki H, Morris JS, Li Y et al. Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene polymorphisms with smoking and dietary mutagen intake in modification of the risk of pancreatic cancer. Carcinogenesis 2008; 29: 118491.
  • 11
    Hirata H, Hinoda Y, Okayama N et al. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 2008; 112: 196473.
  • 12
    Landi S, Gemignani F, Moreno V et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 2005; 15: 53546.
  • 13
    Rebbeck TR, Troxel AB, Walker AH et al. Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol Biomarkers Prev 2007; 16: 44450.
  • 14
    Tsukino H, Kuroda Y, Nakao H et al. Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol 2004; 130: 99106.
  • 15
    International Hepatology Informatics Group. Diseases of the liver biliary tract. Standardization of nomenclature and diagnostic criteria and prognosis. Proceedings of the International Hepatology Informatics Group, Biennial Scientific Meeting, Sept 3–5, 1990. New York: Raven Press 1994, 47164.
  • 16
    Zhang Y, Jia Y, Liu X, Liu L, Wang Q, Wen A. The effect of transcatheter arterial chemoembolization on phase II drug metabolism enzymes in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 2009 Jun 11. [Epub ahead of print].
  • 17
    Hempel N, Gamage N, Martin JL, McManus ME. Human cytosolic sulfotransferase SULT1A1. Int J Biochem Cell Biol 2007; 39: 6859.
  • 18
    Gamage N, Barnett A, Hempel N et al. Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 2006; 90: 522.
  • 19
    Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005; 97: 12534.
  • 20
    Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006; 6: 94760.
  • 21
    Miller JA. Carcinogenesis by chemicals: an overview, G. H. A. Clowes memorial lecture. Cancer Res 1970; 30: 55976.
  • 22
    McManus ME, Minchin RF, Sanderson N, Schwartz D, Johnson EF, Thorgeirsson SS. Metabolic processing of 2-acetylaminofluorene by microsomes and six highly purified cytochrome P-450 forms from rabbit liver. Carcinogenesis 1984; 5: 171723.
  • 23
    Christians U, Schmitz V, Haschke M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 2005; 1: 6414.
  • 24
    Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 2007; 47: 56678.
  • 25
    Liu L, Klaassen CD. Different mechanism of saturation of acetaminophen sulfate conjugation in mice and rats. Toxi Appl Pharmacol 1996; 139: 12834.